Bisgaard 1993.

Methods	Study Design: Crossover RCT Randomisation: Random stated method not described. Concealment of Allocation: Not stated Double Blinding: No ‐ single blind. Withdrawals / dropouts: Described Adverse events: Described Statistical analysis: Described Jadad Score: 3
Participants	Study site: Outpatients No eligible: Not stated. No randomised: 18 No completed: 14 Sex: Males 9 (64%); Females 5 (36%) Age: mean 27 months. Diagnostic criteria for asthma: Dr diagnosis Inclusion criteria: < 3 yrs age, recurrent wheeze, previous ICS but not in past month. Exclusion criteria: No OCS in past 3 months, exacerbations requiring > 4 puffs beta 2 agonist for > 4 days during study period, temp >38 degrees during study period. Baseline severity of asthma: Not stated
Interventions	1: BUD 800mcg /day 2: BUD 200mcg/day 3. Placebo Delivery device: pMDI plus spacer Duration of treatment: 4wks for each treatment ‐ 12 weeks total. Run in phase: not stated Wash out phase: no washout between treatments Other: rescue meds prn, no other meds allowed, no glucocorticoid ointments.
Outcomes	exacerbations, growth rate, symptoms, rescue meds
Notes	No washout period between treatments
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available